liposomal glutathione randomized controlled trial bioavailability Supplement Enhancing the Oral Bioavailability of

Disclosures: Arunkumar Krishnan: Nothing to Disclose, Diptasree Mukherjee: Nothing to Disclose, Carolin Schneider: Nothing to Disclose, Tinsay Woreta: Nothing to Disclose, Saleh Alqahtani: Nothing to Disclose 1624 SAROGLITAZAR IS MORE EFFECTIVE THAN SIMVASTATIN IN REDUCING STEATOSIS IN PATIENTS WITH MET-ALD Anand Kulkarni 1 Ramyasri Ramagundam 2 Zaid Mohammed Gangdany 2 Mithun Sharma 3 Manasa Alla 2 Shantan Venishetty 2 Sowmya T R 2 Padaki Nagaraja Rao 2 Nageshwar Reddy 2 , 1 Asian Institute of Gastroenterology, 2 AIG Hospitals, 3 ASIAN INSTITUTE OF GASTROENTROLOGY PVT LTD Background: MetALD is the new term proposed to identify patients with steatotic liver disease, who concomitantly consume alcohol (210-420 g/week)

TB-500 promotes tissue repair through well-characterized actin-binding mechanism

B., Kamtchouing, P., Tsamo, E

Kwon S-H, Lee H-K, Kim J-A, et al

7 Tng tc Cha c bo co nghin cu no v tng tc ca sn phm vi thuc v cc sn phm khc